Literature DB >> 22622402

Linezolid limits burden of methicillin-resistant Staphylococcus aureus in biofilm of tracheal tubes.

Laia Fernández-Barat1, Miquel Ferrer, Josep Maria Sierra, Dolors Soy, Laura Guerrero, Jordi Vila, Gianluigi Li Bassi, Núria Cortadellas, Pilar Martínez-Olondris, Montserrat Rigol, Mariano Esperatti, Néstor Luque, Lina María Saucedo, Carlos Agustí, Antoni Torres.   

Abstract

OBJECTIVE: To evaluate the effects of systemic treatment with linezolid compared with vancomycin on biofilm formation in mechanically ventilated pigs with severe methicillin-resistant Staphylococcus aureus-induced pneumonia.
DESIGN: Prospective randomized animal study.
SETTING: Departments of Pneumology, Microbiology, and Pharmacy of the Hospital Clínic, Barcelona, and Scientific and Technological Services of the University of Barcelona.
SUBJECTS: We prospectively analyzed 70 endotracheal tube samples. Endotracheal tubes were obtained from pigs either untreated (controls, n=20), or treated with vancomycin (n=32) or linezolid (n=18).
INTERVENTIONS: The endotracheal tubes were obtained from a previous randomized study in tracheally intubated pigs with methicillin-resistant Staphylococcus aureus severe pneumonia, and mechanically ventilated for 69±16 hrs.
MEASUREMENTS AND MAIN RESULTS: Distal and medial hemisections of the endotracheal tube were assessed to quantify methicillin-resistant Staphylococcus aureus burden, antibiotic biofilm concentration by high-performance liquid chromatography or bioassay, and biofilm thickness through scanning electron microscopy. We found a trend toward a significant variation in biofilm methicillin-resistant Staphylococcus aureus burden (log colony-forming unit/mL) among groups (p=.057), and the lowest bacterial burden was found in endotracheal tubes treated with linezolid (1.98±1.68) in comparison with untreated endotracheal tubes (3.72±2.20, p=.045) or those treated with vancomycin (2.97±2.43, p=.286). Biofilm linezolid concentration was 19-fold above the linezolid minimum inhibitory concentration, whereas biofilm vancomycin concentration (1.60±0.91 µg/mL) was consistently below or close to the vancomycin minimum inhibitory concentration. Biofilm was thicker in the vancomycin group (p=.077).
CONCLUSIONS: Systemic treatment with linezolid limits endotracheal tube biofilm development and methicillin-resistant Staphylococcus aureus burden. The potential clinical usefulness of linezolid in decreasing the risk of biofilm-related respiratory infections during prolonged tracheal intubation requires further investigation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22622402     DOI: 10.1097/CCM.0b013e31825332fc

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  10 in total

Review 1.  Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world?

Authors:  Alejandro Beceiro; María Tomás; Germán Bou
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

2.  Bacteriophage Lysin CF-301, a Potent Antistaphylococcal Biofilm Agent.

Authors:  Raymond Schuch; Babar K Khan; Assaf Raz; Jimmy A Rotolo; Michael Wittekind
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

3.  Treatment of Pseudomonas aeruginosa Biofilm Present in Endotracheal Tubes by Poly-l-Lysine.

Authors:  Mustapha Si-Tahar; Virginie Hervé; Antoine Guillon; Delphine Fouquenet; Eric Morello; Clémence Henry; Sonia Georgeault
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

4.  Endotracheal tube biofilm translocation in the lateral Trendelenburg position.

Authors:  Gianluigi Li Bassi; Laia Fernandez-Barat; Lina Saucedo; Valeria Giunta; Joan Daniel Marti; Otavio Tavares Ranzani; Eli Aguilera Xiol; Montserrat Rigol; Ignasi Roca; Laura Muñoz; Nestor Luque; Mariano Esperatti; Maria Adela Saco; Jose Ramirez; Jordi Vila; Miguel Ferrer; Antoni Torres
Journal:  Crit Care       Date:  2015-02-27       Impact factor: 9.097

Review 5.  From in vitro to in vivo Models of Bacterial Biofilm-Related Infections.

Authors:  David Lebeaux; Ashwini Chauhan; Olaya Rendueles; Christophe Beloin
Journal:  Pathogens       Date:  2013-05-13

6.  Eradication of P. aeruginosa biofilm in endotracheal tubes based on lock therapy: results from an in vitro study.

Authors:  María Jesús Pérez-Granda; María Consuelo Latorre; Beatriz Alonso; Javier Hortal; Rafael Samaniego; Emilio Bouza; María Guembe
Journal:  BMC Infect Dis       Date:  2017-12-04       Impact factor: 3.090

7.  Diagnostic Value of Endotracheal Aspirates Sonication on Ventilator-Associated Pneumonia Microbiologic Diagnosis.

Authors:  Laia Fernández-Barat; Ana Motos; Otavio T Ranzani; Gianluigi Li Bassi; Elisabet Aguilera Xiol; Tarek Senussi; Chiara Travierso; Chiara Chiurazzi; Francesco Idone; Laura Muñoz; Jordi Vila; Miquel Ferrer; Paolo Pelosi; Francesco Blasi; Massimo Antonelli; Antoni Torres
Journal:  Microorganisms       Date:  2017-09-20

8.  Assessment of in vivo versus in vitro biofilm formation of clinical methicillin-resistant Staphylococcus aureus isolates from endotracheal tubes.

Authors:  Laia Fernández-Barat; Soumaya Ben-Aicha; Anna Motos; Jordi Vila; Francesc Marco; Montserrat Rigol; Laura Muñoz; Gianluigi Li Bassi; Miquel Ferrer; Antoni Torres
Journal:  Sci Rep       Date:  2018-08-09       Impact factor: 4.379

Review 9.  Challenges in the Microbiological Diagnosis of Implant-Associated Infections: A Summary of the Current Knowledge.

Authors:  Alessandra Oliva; Maria Claudia Miele; Dania Al Ismail; Federica Di Timoteo; Massimiliano De Angelis; Luigi Rosa; Antimo Cutone; Mario Venditti; Maria Teresa Mascellino; Piera Valenti; Claudio Maria Mastroianni
Journal:  Front Microbiol       Date:  2021-10-29       Impact factor: 5.640

10.  Indwelling Device-Associated Biofilms in Critically Ill Cancer Patients-Study Protocol.

Authors:  Olguta Lungu; Ioana Grigoras; Olivia Simona Dorneanu; Catalina Lunca; Teodora Vremera; Stefania Brandusa Copacianu; Iuliu Ivanov; Luminita Smaranda Iancu
Journal:  Pathogens       Date:  2021-03-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.